Medicamen Biotech Limited · NSE:MEDICAMEQ
Medicamen Biotech — Investor Presentation (June 2022)
11 slides from Medicamen Biotech's investor presentation, June 2022
Slide 1: Investor Presentation
Investor Presentation Committed for affordable quality through improvement and technology Medicamen Biotech Limited
Slide 2: Safe Harbour Statement
Safe Harbour Statement This document contains certain forward looking statements with respect to the financial condition, results of operations and business of Medicamen Biotech Limited (“MBL”) and certain of the plans and objectives of MBL with respect to these items. By their nature, forward looki
Slide 3: Medicamen Biotech Limited – An overview
Medicamen Biotech Limited – An overview An Overview of Company ➢ Medicamen Biotech was established in 1996 and is engaged in manufacturing of diverse range of pharmaceutical products Oral Solids, Oral Liquids, ointment for non-oncology products range and it also produces tablet, capsule/lyophilized/
Slide 4: Current Business
Medicamen Biotech Limited Current Business ➢MBL’s Bhiwadi plant is approved in more than 30 countries having around 125 product registrations. ➢Currently company is working with over 150 SKU across 20 different therapeutic segments. ➢Top Therapeutic segments include Antibiotics, Antifungal, Anti pai
Slide 5: Global Presence
Global Presence CIS (Kazakhsthan, South Asia Tajikhstan) Afghanistan etc. India Carribean Island (Cuba, Domino Republic, Curacao, Jamica, Haiti) S.E. Asia (Bhutan, Cambodia, Brazil Philippines) Australia Africa (Nigeria, Ethiopia, Ghana, Zimbabwe, Uganda, Kenya) 5
Slide 6: Future Growth Plan – Oncology Segment
Future Growth Plan – Oncology Segment ➢Started ethical marketing of the Oncology products in India with a team of 25 senior executives in four zones. ➢MBL has launched three Oncology products in the month of January, and it has already launched eight products as on date. ➢MBL has plans to file two A
Slide 7: Future Growth Plan – Product Profile
Future Growth Plan – Product Profile 7
Slide 8: Future Growth Plan – Product Profile
Future Growth Plan – Product Profile 8
Slide 9: Future Growth Plan – Product Profile
Future Growth Plan – Product Profile 9
Slide 10: Future Growth Plan-Marketing Network in Africa
Future Growth Plan-Marketing Network in Africa ➢MBL intends to create it’s own marketing ➢ MBL has already recruited a senior network in ten Francophone countries by executive who is based in Ghana, the using distributing network of Euro Pharma, marketing companies have also been Paris which holds 1
Slide 11: Thank you!
Thank you! Medicamen Biotech Limited REGISTERED OFFICE 1506, Chiranjiv Tower, 43 Nehru Place, New Delhi - 110019 Phone 011-47589500 (30 Lines) | Fax 011-26213081 | E-mail cs@medicamen.com Website www.medicamen.com
Medicamen Biotech — Investor Presentation (June 2022) on 6ix